4. Effect estimates (network meta‐analysis).
| All‐cause mortality | Ceftriaxone | Cefotaxime | Ciprofloxacin | Ceftazidime | Amikacin | Cefixime | Cefonicid | Meropenem + daptomycin | Ofloxacin |
| Ceftriaxone | ‐ | 0.58[0.11,2.54] | 0.63[0.12,2.88] | ‐ | ‐ | 1.26[0.27,7.01] | 1.29[0.53,3.23] | ‐ | ‐ |
| Cefotaxime | 0.56[0.11,2.28] | ‐ | 1.13[0.20,6.67] | ‐ | 1.40[0.36,5.85] | ‐ | ‐ | ‐ | 1.01[0.44,2.36] |
| Ciprofloxacin | 0.65[0.12,2.72] | 1.16[0.20,6.90] | ‐ | 1.76[0.72,4.66] | ‐ | ‐ | ‐ | ‐ | ‐ |
| Ceftazidime | 1.15[0.17,6.37] | 2.08[0.28,15.24] | 1.77[0.73,4.58] | ‐ | ‐ | ‐ | ‐ | 0.56[0.10,2.47] | ‐ |
| Amikacin | 0.76[0.09,5.90] | 1.39[0.35,6.00] | 1.20[0.13,11.68] | 0.67[0.06,7.62] | ‐ | ‐ | ‐ | ‐ | ‐ |
| Cefixime | 1.26[0.26,6.90] | 2.32[0.27,23.93] | 1.99[0.23,21.07] | 1.11[0.11,13.68] | 1.66[0.12,25.20] | ‐ | ‐ | ‐ | ‐ |
| Cefonicid | 1.30[0.52,3.24] | 2.34[0.43,15.52] | 2.02[0.36,13.61] | 1.14[0.16,9.30] | 1.68[0.18,17.44] | 1.02[0.15,6.39] | ‐ | ‐ | ‐ |
| Meropenem + daptomycin | 0.64[0.05,6.13] | 1.16[0.09,13.48] | 1.00[0.15,5.60] | 0.57[0.11,2.41] | 0.83[0.04,13.94] | 0.50[0.03,7.76] | 0.49[0.03,5.81] | ‐ | ‐ |
| Ofloxacin | 0.56[0.09,2.93] | 1.01[0.44,2.35] | 0.87[0.12,6.19] | 0.49[0.06,4.25] | 0.73[0.14,3.63] | 0.43[0.04,4.34] | 0.43[0.05,2.87] | 0.87[0.06,12.52] | ‐ |
| Proportion of people with any adverse event | Ceftriaxone | Cefotaxime | Ciprofloxacin | Ceftazidime | Amikacin | Cefonicid | Meropenem + daptomycin | ‐ | |
| Ceftriaxone | ‐ | 0.65[0.14,2.69] | 1.03[0.25,4.33] | ‐ | ‐ | 1.00[0.10,10.23] | ‐ | ||
| Cefotaxime | 0.64[0.15,2.62] | ‐ | 1.60[0.36,7.38] | ‐ | 1.07[0.10,11.19] | ‐ | ‐ | ||
| Ciprofloxacin | 1.02[0.24,4.16] | 1.59[0.36,7.46] | ‐ | 1.95[0.86,4.49] | ‐ | ‐ | ‐ | ||
| Ceftazidime | 1.97[0.38,10.18] | 3.06[0.56,17.74] | 1.93[0.87,4.47] | ‐ | ‐ | ‐ | 0.61[0.10,3.56] | ||
| Amikacin | 0.69[0.04,10.94] | 1.07[0.10,11.31] | 0.66[0.04,10.95] | 0.34[0.02,6.58] | ‐ | ‐ | ‐ | ||
| Cefonicid | 1.00[0.10,10.16] | 1.58[0.10,24.34] | 0.98[0.06,14.86] | 0.51[0.03,8.72] | 1.47[0.04,54.82] | ‐ | ‐ | ||
| Meropenem + daptomycin | 1.20[0.10,13.53] | 1.88[0.15,22.83] | 1.17[0.16,8.47] | 0.61[0.09,3.62] | 1.72[0.06,52.67] | 1.18[0.04,34.61] | ‐ | ||
| Resolution of SBP | Ceftriaxone | Cefotaxime | Ciprofloxacin | Ceftazidime | Amikacin | Cefixime | Meropenem + daptomycin | Ofloxacin | ‐ |
| Ceftriaxone | ‐ | 0.95[0.41,2.15] | 0.93[0.69,1.25] | ‐ | ‐ | 0.78[0.32,1.88] | ‐ | ‐ | |
| Cefotaxime | 0.90[0.42,1.86] | ‐ | 1.08[0.45,2.53] | ‐ | 0.59[0.25,1.34] | ‐ | ‐ | 1.23[0.75,2.06] | |
| Ciprofloxacin | 0.93[0.69,1.25] | 1.03[0.50,2.24] | ‐ | 1.05[0.64,1.72] | ‐ | ‐ | ‐ | ‐ | |
| Ceftazidime | 0.97[0.55,1.72] | 1.08[0.44,2.71] | 1.05[0.64,1.72] | ‐ | ‐ | ‐ | 1.32[0.51,3.46] | ‐ | |
| Amikacin | 0.54[0.17,1.62] | 0.60[0.25,1.38] | 0.58[0.18,1.78] | 0.55[0.16,1.86] | ‐ | ‐ | ‐ | ‐ | |
| Cefixime | 0.78[0.32,1.90] | 0.87[0.28,2.76] | 0.85[0.33,2.14] | 0.80[0.28,2.31] | 1.47[0.35,6.11] | ‐ | ‐ | ‐ | |
| Meropenem + daptomycin | 1.29[0.43,3.92] | 1.43[0.39,5.38] | 1.38[0.48,4.08] | 1.32[0.52,3.51] | 2.40[0.51,11.53] | 1.64[0.40,6.83] | ‐ | ‐ | |
| Ofloxacin | 1.12[0.45,2.70] | 1.24[0.76,2.06] | 1.21[0.48,2.92] | 1.15[0.41,3.23] | 2.08[0.79,5.66] | 1.43[0.40,5.03] | 0.87[0.21,3.53] | ‐ | |
| Other decompensation | Ceftriaxone | Cefotaxime | Ciprofloxacin | Ceftazidime | Amikacin | Meropenem + daptomycin | Ofloxacin | ‐ | |
| Ceftriaxone | ‐ | 1.21[0.43,3.48] | 1.01[0.31,3.13] | ‐ | ‐ | ‐ | ‐ | ||
| Cefotaxime | 1.22[0.43,3.53] | ‐ | 0.82[0.26,2.40] | ‐ | 1.05[0.11,10.05] | ‐ | 0.92[0.43,1.95] | ||
| Ciprofloxacin | 1.01[0.32,3.16] | 0.83[0.27,2.46] | ‐ | 1.40[0.78,2.51] | ‐ | ‐ | ‐ | ||
| Ceftazidime | 1.43[0.40,5.19] | 1.18[0.33,3.97] | 1.42[0.81,2.50] | ‐ | ‐ | 1.52[0.72,3.32] | ‐ | ||
| Amikacin | 1.28[0.11,15.66] | 1.05[0.11,10.27] | 1.27[0.10,15.24] | 0.89[0.07,11.72] | ‐ | ‐ | ‐ | ||
| Meropenem + daptomycin | 2.19[0.49,9.49] | 1.81[0.41,7.57] | 2.17[0.85,5.64] | 1.53[0.73,3.31] | 1.72[0.12,24.31] | ‐ | ‐ | ||
| Ofloxacin | 1.12[0.31,4.09] | 0.92[0.43,1.96] | 1.10[0.30,4.24] | 0.78[0.19,3.35] | 0.88[0.08,9.51] | 0.51[0.10,2.63] | ‐ | ||
| Length of hospital stay | Cefotaxime | Amikacin | Ofloxacin | ‐ | |||||
| Cefotaxime | ‐ | 1.01[‐4.47,6.41] | ‐0.99[‐4.07,2.09] | ||||||
| Amikacin | 1.01[‐4.43,6.47] | ‐ | ‐ | ||||||
| Ofloxacin | ‐0.99[‐4.02,2.02] | ‐2.03[‐8.30,4.25] | ‐ | ||||||
Abbreviations: SBP: spontaneous bacterial peritonitis
The table provides the effect estimates (proportion of people with any adverse events; hazard ratio for all‐cause mortality and spontaneous resolution for SBP; rate ratio for other decompensation; and mean difference in days for length of hospital stay) of each pairwise comparison for the different outcomes. The top half of the table indicates the effect estimates from the direct comparisons. The bottom half of the table indicates the effect estimates from the network meta‐analysis. For network meta‐analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row corresponding to intervention A and the column corresponding to intervention B for the direct effect estimate. If that cell is empty (indicated by a '‐'), look at the row corresponding to intervention B and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that occupies the column corresponding to intervention A and the row corresponding to intervention B for the direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no direct comparison.
There were no significant differences in the effect estimates for any of the comparisons in any of the outcomes for which network meta‐analysis could be performed.